Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 143

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 143
---
 performing at a high level, or if mitigation measures we may take to respond to a decrease in labor availability have unintended negative effects (such as higher wages or other benefits), our business, financial condition, results of operations and growth prospects could be adversely affected. Additionally, the operations of our vendors and partners could also suffer from labor shortages, turnover, and labor cost increases which could result in supply chain disruptions and increases in the costs of the products and services we purchase, each of which could adversely affect our operations. Our business and reputation will suffer if we are unable to establish and comply with stringent quality standards to assure that the highest level of quality is observed in the performance of our tests. Inherent risks are involved in providing tests and related services for prevention, oncology, reproductive genetics and rare and complex disease diagnostics. Consumers, patients and healthcare providers rely on us to provide accurate clinical and diagnostic information that may be used to make critical healthcare and lifestyle decisions. As such, users of our tests may have a greater sensitivity to errors than users of some other types of products and services. We must maintain top service standards and other quality controls. Past or future performance or accuracy defects, incomplete or improper process controls, excessively slow turnaround times, unanticipated uses of our tests or mishandling of samples or test results (whether by us, patients, healthcare providers, courier delivery services, or others) can lead to adverse outcomes for our customers and interruptions to our services. These events could lead to voluntary or legally mandated safety alerts relating to our tests or our laboratory facilities and could result in the removal of our products and services from the market or the suspension of our laboratories’ operations. Insufficient quality controls and any resulting negative outcomes could result in significant costs and litigation, as well as negative publicity that could reduce demand for our tests and payers’ willingness to cover our tests. Even if we maintain adequate controls and procedures, damaging and costly errors may occur. The occurrence of any of these events could have an adverse impact on our business, financial condition, results of operations and growth prospects. Our future AI Agents business will significantly depend upon third -party infrastructures, including language models and other AI technologies, which are subject to developing regulatory frameworks. We are currently in the research and development phase of AI Agents designed to support and scale our health management services. While we expect that the first commercial use of our AI Agents may begin as early as 2026, this timeline is subject to several risks and uncertainties. These include the continued progress in foundational large language models (LLMs